[{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SI-B001","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Axitinib","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SI-B001","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SI-B001","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNC-038","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNC-038","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNC-038","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNC-038","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GNC-035","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BL-M02D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GNC-035","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-B16D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-B16D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-B16D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-M08D1","moa":"||Trop-2","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BL-M08D1","moa":"||Trop-2","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BL-M09D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-M11D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-M17D1","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-M17D1","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GNC-038","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNC-039","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNC-035","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNC-035","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNC-035","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BL-M02D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BL-M02D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL-M05D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BL-M14D1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GNC-077","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GNC-077","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GNC-077","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GNC-038","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GNC-038","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"}]
Find Clinical Drug Pipeline Developments & Deals by Baili Pharmaceutical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
